Pulmatrix Inc (NASDAQ: PULM), a clinical stage biopharmaceutical company, announced yesterday that it has named Rick Batycky, PhD as its new director.

Dr Batycky has more than two decades of experience with biotech start-ups from founding to acquisition across an array of platforms and disease states with significant expertise in inhaled drug development. He is presently the CEO at Nocion Therapeutics. Most recently, he was the chief scientific officer and a founder of Civitas Therapeutics, which was acquired by Acorda. At Acorda, he was chief technology officer and he led its novel dry powder inhalation therapy to treat motor issues in Parkinson's patients through to FDA approval as Inbrija. Prior to that he was chief scientific officer and senior VP of R&D at Pulmatrix and held prior positions at Alkermes and Advanced Inhalation Research.

Ted Raad, chief executive officer for Pulmatrix, said, 'Rick brings deep expertise in drug development to the board and we are thrilled to welcome him. His broad ranging experience in respiratory therapeutics, including Pulmatrix's iSPERSE dry powder inhalation technology will be invaluable as we consider opportunities to bring new therapeutics to market. We look forward to his strategic guidance as we strategically advance our iSPERSE platform.'